Germany· DE-A57-426eab90c3c8a6ba
Cecenu®
A lomustine product containing lomustine, registered in Germany by Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel). The same ATC class is registered in 10 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Lomustine is registered in 10 of 19 countries.
Countries holding a registration under ATC L01AD02 (lomustine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 4 of them publish a price we can compare per daily dose
Lomustine · ATC L01AD02
10 / 19 countries
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Netherlands
- Norwayprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Lomustine
- Manufacturer
- Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
- Country
- Germany (DE)
- ATC code
- L01AD02
- ATC class
- Lomustine
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
166 interactions on record for lomustine.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lomustine · interactions on record
166 records
- 36 severe
- 112 moderate
- 18 minor
Most severe, free to view
- CimetidineA02BA01severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Nalidixic acidJ01MB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lomustine in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesGleostineAzurity Pharmaceuticals, Inc.
- United KingdomCeeNU 100mg capsulesImported (United States)
- NorwayCeenuBristol-Myers Squibb
- CanadaCEENUBRISTOL-MYERS SQUIBB CANADA
- NetherlandsLomustine BModesto capsules, hard 40 mgBModesto B.V.
- FinlandLomustine medacMedac Gesellschaft Für Klinische Spezialpräparate mbH
- FranceLOMUSTINE MEDAC 40 mg, géluleMEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE (ALLEMAGNE)
- SwedenLomustine Medac 40 mg Kapsel, hårdmedac Gesellschaft für klinische Spezialpräparate mbH
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Austria · Lomustin (Ccnu) Medac
- Denmark · Lomustine Medac
- Finland · Lomustine Medac
- France · Lomustine Medac
- United Kingdom (Northern Ireland) · Lomustine Medac
- Sweden · Lomustine
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6557c7c-b6a4-44b4-ace5-54bdae4630f3 GET /v1/drugs/b6557c7c-b6a4-44b4-ace5-54bdae4630f3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Lomustine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about lomustine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.